CLINICAL TRIALS PROFILE FOR CELECOXIB

505(b)(2) Clinical Trials for celecoxib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00177853 ↗	Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer	Terminated	Pharmacia and Upjohn	Phase 1	2006-12-01	The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.
New Combination	NCT00177853 ↗	Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer	Terminated	University of Pittsburgh	Phase 1	2006-12-01	The purposes of this study are to examine the effects of a new combination of drugs, celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people before they undergo surgery; to determine what effects this combination has on pancreatic cancer; and to determine the highest dose of celecoxib and irinotecan that can be given safely without causing severe side effects. While not an endpoint, it is hoped that this combination will also shrink tumors enough for excision.
New Combination	NCT00230399 ↗	Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer	Completed	University of Michigan Cancer Center	Phase 2	2003-06-01	This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.
New Combination	NCT00230399 ↗	Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer	Completed	University of Michigan Rogel Cancer Center	Phase 2	2003-06-01	This study will examine a new combination of drugs: celecoxib, capecitabine and irinotecan, for the treatment of metastatic colorectal cancer. Capecitabine and irinotecan, individually, are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of these two drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination of capecitabine and irinotecan has a positive effect on metastatic colorectal cancer. Likewise, previous research in animals has shown that celecoxib, a drug approved for arthritis therapy, also has activity against this tumor type and may improve the anti-cancer activity of the combination of capecitabine and irinotecan.
New Formulation	NCT00925106 ↗	Pharmacokinetics Of Celecoxib Test Formulations	Completed	Pfizer	Phase 1	2009-07-01	The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.
New Formulation	NCT00925106 ↗	Pharmacokinetics Of Celecoxib Test Formulations	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 1	2009-07-01	The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.
New Combination	NCT02641314 ↗	Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma	Recruiting	University of Cologne	Phase 2	2016-12-22	Neuroblastoma is the second most frequent cause for death from cancer in childhood. Already one year after diagnosis of recurrence from high risk neuroblastoma, 75% of the patients experience further progression. Metronomic therapy is targeting not only the tumor cell, but also the tumor supplying vasculature and the interactions between Tumor and immune cells. The toxicity is expected to be low due to the low (but continuous) dosing of drugs. The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected.

All Clinical Trials for celecoxib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001693 ↗	Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers	Completed	National Cancer Institute (NCI)	Phase 1	1998-03-01	This is a randomized, placebo-controlled Phase I/II multi-center trial, of the safety and efficacy of Celecoxib in a cohort of 81 HNPCC subjects and gene carriers. The three proposed intervention arms are: Celecoxib (to be provided by Searle) will be administered at 200mg p.o. BID x 12 months or 400mg p.o. BID x 12 months vs. Placebo p.o. BID x 12 months. Assessment of endoscopic and tissue-based biomarker endpoints will be conducted at baseline and 12 months on study drug or placebo. Patients that present with polyps at baseline will undergo a month 4 endoscopy. Plasma drug trough samples for pharmacokinetic analyses will be collected at baseline and month 12. NCI-Chemoprevention Branch will coordinate the efforts and activities of all sites. Safety monitoring will occur via in-patient interviews with exams at month twelve; symptom questionnaires completed at baseline, months one, four, eight and twelve; blood and urinalysis at baseline and at months one, four, eight and twelve. A post-administration telephone call to evaluate side effect resolution will occur at months 13-14 for patients who have unresolved adverse events at the end of month 12.
NCT00001955 ↗	Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1999-12-01	This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with temporomandibular disorder (TMD). Part 1 will evaluate celecoxib (Celebrex); Part 2 will evaluate etanercept (Enbrel). The Food and Drug Administration has approved both of these drugs for treating certain forms of arthritis. Patients between the ages of 18 and 65 years with painful jaw joint conditions may be eligible for this study. Candidates will complete several written questionnaires about their jaw condition and will undergo a medical history, complete TMD evaluation, blood and urine tests, and imaging studies of the temporomandibular joint, such as X-rays and magnetic resonance imaging. Patients will rate the quality and intensity of their pain before beginning treatment. At certain periods during the study, they will also keep a pain diary, twice a day recording the intensity and magnitude of their pain. Part 1 - Celecoxib: Patients will be randomly assigned to receive either 1) celecoxib twice a day by mouth; 2) naproxen (a non-steroidal anti-inflammatory drug) twice a day by mouth; or 3) a placebo (inactive pill) twice a day by mouth. Part 2 - Etanercept: Patients will be randomly assigned to receive either 1) etanercept injected under the skin or 2) saline (an inactive placebo) injected under the skin. Patients in this group will also undergo two aspirations of fluid from the jaw joint - once before treatment begins and again 6 weeks later. For this procedure, the joint is numbed with an anesthetic and then a needle is inserted into the jaw space to withdraw fluid, which will be analyzed for inflammatory processes in the joint. All patients will have a final evaluation 6 weeks after beginning treatment, including a TMD physical examination, laboratory and X-ray tests as required. The pain diary and questionnaires will be collected at this visit.
NCT00005094 ↗	Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps	Completed	National Cancer Institute (NCI)	Phase 3	2000-03-01	Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of celecoxib has been approved for use in reducing the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP). It is not known whether there is a clinical benefit from a reduction in the number of colorectal polyps in FAP patients. The use of celecoxib may be an effective way to prevent the development of sporadic adenomatous polyps, precursors of colorectal cancer. This randomized phase III trial is studying celecoxib to see how well it works compared to a placebo in preventing the development of adenomatous colorectal polyps in patients who have had at least one polyp removed.
NCT00005878 ↗	Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus	Completed	National Cancer Institute (NCI)	Phase 2	2000-07-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.
NCT00005878 ↗	Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2000-07-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.
NCT00005878 ↗	Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2000-07-01	RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Celecoxib may be effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing cancer in patients who have Barrett's esophagus.
NCT00006124 ↗	Celecoxib in Treating Patients With Bladder Cancer	Completed	National Cancer Institute (NCI)	Phase 2/Phase 3	2000-06-01	This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer

Clinical Trial Conditions for celecoxib

Condition Name

Condition Name for celecoxib
Intervention	Trials
Osteoarthritis	36
Colorectal Cancer	26
Lung Cancer	23
Breast Cancer	22

Condition MeSH

Condition MeSH for celecoxib
Intervention	Trials
Osteoarthritis	77
Pain, Postoperative	48
Osteoarthritis, Knee	45
Colorectal Neoplasms	43

Clinical Trial Locations for celecoxib

Trials by Country

Trials by Country for celecoxib
Location	Trials
United Kingdom	131
Canada	97
Japan	59
China	49
Brazil	47

Trials by US State

Trials by US State for celecoxib
Location	Trials
New York	75
Texas	73
California	65
Illinois	56
Pennsylvania	55

Clinical Trial Progress for celecoxib

Clinical Trial Phase

Clinical Trial Phase for celecoxib
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	15

Clinical Trial Status

Clinical Trial Status for celecoxib
Clinical Trial Phase	Trials
Completed	324
Recruiting	74
Terminated	65

Clinical Trial Sponsors for celecoxib

Sponsor Name

Sponsor Name for celecoxib
Sponsor	Trials
National Cancer Institute (NCI)	98
Pfizer	77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	35

Sponsor Type

Sponsor Type for celecoxib
Sponsor	Trials
Other	602
Industry	247
NIH	119

Last updated: May 21, 2026

Celecoxib Clinical Trials Update, Market Analysis, and Exclusivity/Generic-Lifecycle Projections

Celecoxib is an oral, COX-2 selective NSAID. Commercially, it is a mature, largely off-patent product in most major markets, with ongoing life-cycle IP primarily around specific formulations, combinations, dosing regimens, and country-specific method-of-use/packaging protections. Clinical development is currently dominated by incremental studies (new dosing strategies, pain/arthritis subpopulations, and comparative safety/efficacy in routine-care settings) rather than new “platform” indications in the way seen for novel NMEs. Net effect: near-term market growth is driven more by substitution dynamics, price erosion, and regional access than by pipeline breakthroughs.

Market projection for celecoxib is therefore best framed as a volume-and-price story: modest global growth is possible through population and guideline-driven use, but value growth is constrained by sustained generic competition and periodic reformulation-based brand survivals in select jurisdictions.

---

What clinical trials are evaluating celecoxib right now (2024 2025 update)?

Featured-signal status from the last two years: the celecoxib clinical trial landscape is dominated by interventional comparative studies, real-world effectiveness/safety follow-ups, and formulation or regimen optimization. Trial targets typically map to:

• Osteoarthritis (OA) pain and functional endpoints
• Rheumatoid arthritis (RA) symptom control in specific subgroups
• Acute musculoskeletal pain settings (often post-procedure, sprain/strain, or dental surgery pain models)
• Cardiovascular/renal safety observational frameworks, often stratified by risk factors
• Gastrointestinal (GI) risk and adherence outcomes under routine dosing

Expected endpoints used in current studies

• WOMAC or similar OA pain/function scales
• Rescue analgesic use and time-to-additional analgesia
• Patient-reported outcomes (PROs)
• Safety composites: BP events, edema, renal function markers, GI bleeding proxies
• Discontinuation rates due to AEs

How the current trial pattern affects competitive positioning

• These trials support label maintenance or incremental claims rather than new exclusivity reset strategies on their own.
• They are commonly used in markets where originators have already lost primary composition-of-matter exclusivity, helping sustain premium positioning via “differentiated” claims for specific strengths/form factors or patient subsets.

---

How does celecoxib’s clinical pipeline compare with other NSAIDs (ibuprofen naproxen diclofenac) on efficacy and safety?

Comparative positioning

• Celecoxib’s core differentiation remains COX-2 selectivity, which typically lowers GI toxicity relative to nonselective NSAIDs in comparable populations.
• Comparative safety is trade-off driven: cardiovascular and renal risk narratives stay sensitive to baseline comorbidities and dose/duration.

Typical trial design patterns that show up repeatedly

• Active-comparator nonselective NSAIDs for GI tolerability comparisons
• Head-to-head trials or network meta-analyses for pain and functional improvement
• Risk-stratified substudies to estimate incidence of edema, BP elevation, creatinine rise

Market impact

• Where clinicians prioritize GI tolerability, celecoxib-based therapies hold share versus ibuprofen/naproxen, but value is diluted by generic availability.
• In markets where prescribers default to inexpensive nonselectives, celecoxib growth tends to track guideline nuances rather than clinical “advantage” alone.

---

Which formulation and dosing studies are most common for celecoxib (IR vs ER) and what are they testing?

Celecoxib exists in immediate-release (IR) and extended-release (ER) formats (depending on jurisdiction and brand). Current “life-cycle” studies typically test:

• Lower-dose strategies for similar analgesic effect with fewer AEs
• ER regimens that target fewer daily administrations and improved adherence
• Food-effect and pharmacokinetic bridging for generic entrants or reformulated products
• Bioequivalence and performance testing supporting switchability between brand and generic

Why formulation trials matter for exclusivity

• Even when base drug patents expire, countries often retain patentable territory for specific compositions, coatings, ER matrices, and processes.
• A clinically credible PK/PD story can preserve brand presence against therapeutically substitutable generics if the product is supported by protected “use claims” or formulation-specific IP.

---

What patents protect celecoxib in key markets (composition method-of-use and formulation IP)?

Celecoxib’s earliest composition-of-matter protections are long expired in most regions. Protection now concentrates on:

• Formulation patents (ER matrix, specific excipient systems, coating/process)
• Method-of-use patents (specific titration/dosing for defined pain syndromes)
• Country-specific packaging/administration device claims in limited cases
• Secondary patents for polymorphs or manufacturing processes where still enforceable in certain jurisdictions

Practical implication for business

• Any enforcement posture against generics is far more likely to hinge on formulation or method-of-use patents than on primary drug substance patents.
• Litigation and brand licensing behavior reflects this: disputes tend to be product-specific (a particular strength, ER vs IR, or manufacturing route).

---

When does celecoxib lose exclusivity by country (US EU UK Canada Japan)?

US (high-level lifecycle)

• Celecoxib is widely generic; primary patent exclusivity is not a near-term barrier for generic entry.
• The remaining exclusivity risk, where it exists, comes from any still-listed patents in the Orange Book for specific products (formulations/indications) or from litigation settlements that can delay a specific applicant’s launch.

EU/UK

• Similar pattern: composition exclusivity is largely gone, and remaining protection is localized to specific formulations and processes that may still be enforceable in certain member states.

Canada/Japan

• Same general lifecycle dynamic: generic entry dominates; any delay would come from still-pending secondary patents and product-specific regulatory linkages.

Because celecoxib is mature, the actionable takeaway is that “exclusivity calendars” are product-specific, not molecule-specific.

---

What is the Orange Book status of celecoxib (FDA listings and patent hooks)?

For US launch timing, the operational measure is the FDA Orange Book listing for each specific marketed NDA/RLD and strength. In practice for a mature NSAID:

• Multiple generic products are typically already marketed.
• Any remaining “hook” is confined to one or more Orange Book-listed patents tied to a specific RLD product or formulation.

For business planning, the correct process is:

1. Identify the RLD(s) and strengths with any still-active listed patents.
2. Map each listed patent to expected generic paragraph IV or 505(j) pathways.
3. Check whether any active injunctions or FDA “pause” events exist for particular applicants.

This is the only approach that yields enforceable timelines for celecoxib-specific launches in the US.

---

Are there any Paragraph IV challenges for celecoxib in the US (generic launch risks)?

Given the maturity of celecoxib, the probability of recurrent, large-scale Paragraph IV activity is lower than for newer branded products. Where challenges do occur, they tend to be:

• Product-specific (strength, dosage form, ER vs IR)
• Based on infringement carveouts for formulation/process differences
• Tied to Orange Book patents still listed for a given RLD product

For a generic entrant, the launch risk is primarily:

• Patent-by-patent infringement mapping against the Orange Book list for the target RLD
• Litigation timelines and settlement terms that can delay launch even when a patent is expected to expire soon

---

What celecoxib patent litigation affects generics (cases settlements and injunctions)?

Celecoxib litigation historically involved originator versus generic disputes around still-listed patents, including formulation claims. Current “litigation affects launch” scenarios typically emerge when:

• A court issues or threatens an injunction tied to a specific patent
• Settlement agreements include launch-delay covenants for defined claims/products

For market projection, litigation matters only insofar as it changes the expected timing of a specific applicant’s approval-to-market window in the relevant dosage form. If the molecule is already extensively generic, incremental litigation delays do not materially change the overall market but can affect share capture among late entrants.

---

How strong is the patent estate for celecoxib (infringement likelihood and enforcement value)?

As a mature drug:

• Core composition-of-matter estate value is mostly realized and expired.
• The remaining enforceable value is concentrated in a narrower set of secondary patents, often formulation-specific.

Strength characteristics observed in life-cycle NSAID programs

• Secondary patents can be strong if they cover robust manufacturing/process differentiation.
• Weakness arises when patents are broad in claim scope but easy to avoid with standard formulation substitutions, or if generic products use established excipients without infringing the specific claimed matrix/process.

Enforcement value is thus usually limited to:

• The subset of products whose formulations are close enough to claim language
• Countries where courts/jurisdictions interpret the relevant claim elements narrowly or where injunctive relief is reliably obtainable

---

What market size does celecoxib have and how will it evolve over 2024–2029?

Market dynamics that drive projection

1. Generic penetration is already high in most major markets.
2. Price pressure continues as additional manufacturers expand supply.
3. Specialty use persists for patients where GI tolerability and clinician preference keep celecoxib in rotation.
4. ER/optimized regimens can temporarily preserve premium positioning versus cheapest IR generics.
5. Safety communications around cardiovascular/renal risk influence prescriber behavior in comorbidity-heavy populations.

Projection direction

• Global revenue growth is likely modest and driven by volume stability in treated populations plus regional price variations.
• Global unit volume may grow slightly with demographic trends and guideline adherence, but per-unit revenue typically declines over time due to generics.

Most likely forecast shape

• A slowing growth curve that trends toward low-single-digit revenue growth in aggregate markets, with continued share shifts to the lowest-cost, highest-availability generic suppliers.
• In markets where brand-only formulations or ER presentations remain protected, localized revenue resilience can occur, but it typically does not change the global trend.

---

Which companies sell celecoxib and how concentrated is the competitive landscape?

The competitive landscape for celecoxib is typically:

• High generic participation across IR and multiple strengths
• Several branded manufacturers/label holders in certain jurisdictions where brand positioning persists through life-cycle protections or supply contracts

Concentration drivers

• Contracting and tendering: hospital and payer formularies can create short-term concentration by region.
• Supply reliability: fewer suppliers at times can lift pricing temporarily.
• ER scarcity: ER formulations can concentrate share if fewer products meet strict formulation performance criteria.

Business implication

• Expect competitive intensity to remain high, with share moving primarily on price, supply continuity, and formulary access rather than on differentiated clinical outcomes.

---

How does celecoxib compare with celecoxib alternatives for OA and chronic pain (market substitution analysis)?

Common substitution comparators include:

• Nonselective NSAIDs: ibuprofen, naproxen, diclofenac
• COX-2 alternatives: other selective NSAIDs where available
• Non-NSAID pain regimens: topical NSAIDs, acetaminophen, and other analgesic adjuncts

Substitution logic

• If payer systems favor the lowest-cost effective option, celecoxib’s share gains depend on GI-risk patient segments and prescriber behavior.
• If formularies incorporate GI-risk flags and step-therapy rules that consider COX-2 selectivity, celecoxib retains a higher share of the relevant patient funnel.

---

What generic entry risks exist for celecoxib (manufacturing and IP barriers)?

Generic entry risks are mainly operational rather than molecule-level:

• Formulation-specific bioequivalence requirements, especially for ER
• Manufacturing robustness: controlling dissolution profiles and excipient performance
• Patent-by-patent infringement mapping against any still-listed Orange Book patents tied to the target RLD formulation

In practice:

• Most entry risk is mitigated once a generic platform has proven BE and cleared any relevant patent barriers for the specific product.

---

What is the FDA regulatory status of celecoxib (pathways and expected label stability)?

Regulatory status for celecoxib is mature:

• Broad generic coverage via ANDA/505(j) pathways
• Label stability with periodic updates reflecting safety communications and postmarketing evidence

Expected regulatory behavior:

• Continued maintenance of OA/RA and pain indications where still clinically supported
• Periodic safety label changes driven by class-wide NSAID safety surveillance

This matters for projection because it usually does not create new exclusivity but can affect utilization patterns through safety guidance and prescriber risk stratification.

---

Key Takeaways

• Celecoxib is a mature, largely off-patent NSAID in most markets; remaining exclusivity and litigation risk is product-specific (formulation, dosing regimen, ER performance), not molecule-wide.
• Clinical trial activity is dominated by incremental studies and safety/real-world evidence rather than new indication-defining breakthroughs.
• Market outlook through 2024–2029 is best projected as modest value growth with continued pricing pressure from generic competition and occasional localized premium resilience from ER or formulation-differentiated products.
• Generic entry is operationally feasible for well-developed formulations; the binding constraint is patent-by-patent evaluation against Orange Book listings for specific RLD products and strengths.

---

FAQs

1. Does celecoxib have extended-release exclusivity in the US?
   Exclusivity, where any, is tied to specific Orange Book-listed ER patents for particular strengths/products, not to celecoxib as a molecule.

2. Will biosimilars affect celecoxib competition?
   No. Celecoxib is a small molecule; biosimilar frameworks do not apply.

3. Which patient groups maintain higher celecoxib use despite generic competition?
   Patients with GI-risk profiles where prescribers prefer COX-2 selectivity and clinicians follow risk-stratified NSAID selection.

4. What endpoint trends dominate recent celecoxib studies?
   OA/RA pain and function scales plus safety endpoints around renal function, BP/edema, and GI tolerability proxies.

5. How do settlements change generic launch timing for established NSAIDs like celecoxib?
   Settlements can delay a specific applicant’s launch against specific patents even after broader molecule-level exclusivity has expired.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations
3. ClinicalTrials.gov. (n.d.). Celecoxib studies. U.S. National Library of Medicine. https://clinicaltrials.gov/
4. EMA. (n.d.). European Medicines Agency: Celecoxib product information and assessments. European Medicines Agency. https://www.ema.europa.eu/